Skip to main content

Crinetics Presents Clinical and Research Results at ENDO 2022

Written by Customer Service on . Posted in Public Companies.

CRN04894 Selected for Oral Presentation

SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study.

Results from the company’s Phase 1 study of CRN04777, the company’s investigational candidate for the treatment of congenital hyperinsulinism (HI) will be presented as a narrated “Poster Plus.” A late-breaking Poster Plus will also be presented on the company’s preclinical-stage parathyroid hormone (PTH) antagonist for the treatment of hypercalcemia. Poster Plus presenters will participate in Meet-and-Greet sessions and their posters will be accompanied by 5-minute videos for attendees.

Presentation details:
Title:(OR12) Inhibition of Basal and ACTH-Stimulated Cortisol Secretion in Humans Using an Oral, Nonpeptide ACTH Antagonist (CRN04894)
Time:Sunday, June 12, 2022 11:15 a.m. – 11:30 a.m. ET
Location:Oral Session; A404-A405
  
Title:(PSUN304) CRN04777, an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion
Time:Sunday, June 12, 2022 12:30 p.m. – 2:30 p.m. ET
Location:Poster+ Session; Hall A1
  
Title:(LBSAT142) Discovery and Characterization of a Potent and Orally Bioavailable Parathyroid Hormone Receptor Type-1 (PTHR1) Antagonist for the Treatment of Hypercalcemia
Time:Saturday, June 11, 2022 1:00 p.m. – 3:00 p.m. ET
Location:Poster+ Session; Hall A1
  

The posters and oral presentations will be made available on the Crinetics website in accordance with the congress’ embargo policy. For attendees of ENDO 2022, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#822) and in the virtual exhibit hall.

About Crinetics Pharmaceuticals  
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine, a somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777, a somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, and CRN04894, an ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

Contacts: 
Chas Schultz 
VP, IR & Corporate Communications 
cschultz@crinetics.com 
(858) 450-6464 

Investors / Media: 
Corey Davis 
LifeSci Advisors, LLC 
cdavis@lifesciadvisors.com
(212) 915-2577 

Aline Sherwood 
Scienta Communications 
asherwood@scientapr.com
(312) 238-8957 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.